There’s more hopeful data about the coronavirus vaccines that could make many people excited these days. Just earlier today, we revealed that some pretty great news might make a lot of people’s day.
USA Today just noted that Johnson & Johnson released new data, and this shows the fact that a booster dose of its vaccine given two months after the one-shot vaccine provides 94% protection against moderate-to-severe covid symptoms.
J&J cited three studies of the vaccine and said:
“the booster shot offers 100% protection against severe or critical symptoms.”
Anyway, now, new info has been released that brings even more hope that the nightmare could be ending soon thanks to the efficient vaccines.
New protein-based vaccine shows promising efficiency
Check out a really relevant tweet that has been made in this direction.
*Dynavax: COVID-19 Vaccine Developed by Clover Biopharmaceuticals Using Dynavax’s CpG 1018 Adjuvant Meets Primary and Secondary Efficacy Endpoints in Global Phase 2/3 Trial $DVAX
— *Walter Bloomberg (@DeItaone) September 22, 2021
Official data released by her farmaceutical company and cited by the important publication Business Insider shows that Clover Biopharmaceuticals, Ltd. which is a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, and CEPI, the Coalition for Epidemic Preparedness Innovations, has just revealed that Clover’s adjuvanted protein-based covid 19 vaccine candidate, SCB-2019 “achieved the primary efficacy endpoint and secondary efficacy endpoints in SPECTRA, a global pivotal Phase 2/3 clinical trial.”
The vaccine shows efficiency against the Delta variant
Check out what the online publication mentioned above noted:
“Vaccine efficacy was successfully demonstrated in an environment where 100% of SARS-CoV-2 strains observed in the efficacy analysis were variants.”
Business Insider concluded their piece by noting that the overall efficiency was 67% against the covid 19 of any severity caused by any strain that was included in the studies.
The vaccine candidate is one of the first ones that show important efficiency against the Delta variant.
